Biotest
Biotest AG, a leading player in the biopharmaceutical industry, is headquartered in Dreieich, Germany. Founded in 1946, the company has established itself as a pioneer in the development and production of immunoglobulins and blood plasma products. With a strong focus on therapeutic areas such as immunology and haematology, Biotest is committed to enhancing patient care through innovative solutions. The company’s core offerings include high-quality plasma-derived therapies, which are distinguished by their rigorous quality standards and advanced manufacturing processes. Biotest has achieved significant milestones, including the expansion of its global presence, with operations spanning Europe, North America, and Asia. Renowned for its commitment to research and development, Biotest continues to solidify its market position as a trusted provider of essential biopharmaceuticals, contributing to improved health outcomes worldwide.
DitchCarbon Score
How does Biotest's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest's score of 67 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotest's reported carbon emissions
In 2024, Biotest reported total carbon emissions of approximately 16934800 kg CO2e for Scope 1, 25092000 kg CO2e for Scope 2 (market-based), and 92215000 kg CO2e for Scope 3 emissions. This reflects a slight increase in Scope 1 emissions from 15210000 kg CO2e in 2023, while Scope 2 emissions also rose from 21905000 kg CO2e (market-based) in the previous year. Notably, Scope 3 emissions decreased from 102043000 kg CO2e in 2023. Biotest's emissions data is cascaded from its parent company, Grifols, S.A., indicating a corporate family relationship that influences its sustainability reporting. Despite the absence of specific reduction targets or initiatives outlined in their current commitments, the company is part of a broader industry context that increasingly prioritises climate action and transparency. The emissions data highlights the significant impact of Scope 3 emissions, which typically encompass indirect emissions from the supply chain and product use, underscoring the importance of comprehensive strategies to address climate commitments. As Biotest continues to align with industry standards, it remains essential for the organisation to establish clear reduction targets to enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 893,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,537,200 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biotest is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
